Nasdaq
$0.9751▲ 0.35%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $67.1MShares out 68.8M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
10- 10.6Pre-market26.10.06 21:008-KKey event#●●●#●●●#●●●
Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals completed a private placement (PIPE) financing of approximately $5.6 million on October 5, 2026. The company issued 4,843,300 shares of common stock at $1.16 per share, with proceeds intended to support the clinical development of 'Telomir-Zn' for advanced or metastatic triple-negative breast cancer.…more
$0.9751+0.35%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.17Pre-market26.09.17 21:308-KKey event
Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals announced the publication of a peer-reviewed preclinical study in the International Journal of Molecular Sciences, demonstrating that its candidate 'Telomir-Zn' improved visual function and restored retinal structure in an age-related macular degeneration (AMD) model. The company stated that these findings validate the drug's mechanism in metal homeostasis and epigenetic regulation, suggesting potential therapeutic applications beyond its current focus on Phase 1/2 clinical trials for triple-negative breast cancer (TNBC).…more
$0.9751+0.35%vs prev closeView filingShare - 9.16After-hours26.09.17 05:308-KKey event
Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals announced that all three proposals, including the election of directors and the appointment of an independent auditor, were approved at its 2026 Annual Meeting held on September 11, 2026. The meeting saw participation from 47,129,480 shares, representing approximately 68.53% of the 68,774,954 shares outstanding as of the July 21, 2026 record date.…more
$0.9751+0.35%vs prev closeView filingShare
9 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.6Pre-market26.10.06 21:00Bullish#●●●#●●●#●●●
Telomir Pharmaceuticals Secures $5.6 Million in Private Placement
Telomir Pharmaceuticals has raised approximately $5.6 million through a private placement of common stock to fund its operations. The proceeds will primarily support the Phase 1/2 clinical development of its lead oncology candidate, Telomir-Zn.…more
$0.9751+0.35%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.17Pre-market26.09.17 21:30
●●●●●●●● ●●●●● ●●●●●●
Telomir Pharmaceuticals announced that its candidate 'Telomir-Zn' improved visual function and retinal structure in a preclinical model of age-related macular degeneration. These findings are early-stage results and remain separate from the company's primary focus on oncology clinical trials.…more
$0.9751+0.35%vs prev close - 9.14Pre-market26.09.14 21:01
●●●●●●●● ●●●●● ●●●●●●
Telomir Pharmaceuticals announced that its candidate Telomir-Zn demonstrated inhibition of cell growth in both human and canine osteosarcoma models in a study with Ohio State University. These findings provide a translational foundation for further evaluating the compound's therapeutic potential in clinical settings.…more
$0.9751+0.35%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report